HRP20231663T1 - Biciklički derivati heteroarila - Google Patents
Biciklički derivati heteroarila Download PDFInfo
- Publication number
- HRP20231663T1 HRP20231663T1 HRP20231663TT HRP20231663T HRP20231663T1 HR P20231663 T1 HRP20231663 T1 HR P20231663T1 HR P20231663T T HRP20231663T T HR P20231663TT HR P20231663 T HRP20231663 T HR P20231663T HR P20231663 T1 HRP20231663 T1 HR P20231663T1
- Authority
- HR
- Croatia
- Prior art keywords
- amine
- triazolo
- azabicyclo
- oxazepin
- tetrahydro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- RETFIEPIZUQCDL-UHFFFAOYSA-N oxazin-2-amine Chemical compound NN1OC=CC=C1 RETFIEPIZUQCDL-UHFFFAOYSA-N 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- PUVJNVLOUNIHNF-MFGZZSJASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 PUVJNVLOUNIHNF-MFGZZSJASA-N 0.000 claims 2
- FECROEMXGDFEFX-MFGZZSJASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=NC=N1 FECROEMXGDFEFX-MFGZZSJASA-N 0.000 claims 2
- PUVJNVLOUNIHNF-MVGGYSAASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 PUVJNVLOUNIHNF-MVGGYSAASA-N 0.000 claims 2
- FECROEMXGDFEFX-MVGGYSAASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=NC=N1 FECROEMXGDFEFX-MVGGYSAASA-N 0.000 claims 2
- DRMLDDBQPBECRA-GHEUYMLLSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 DRMLDDBQPBECRA-GHEUYMLLSA-N 0.000 claims 2
- DRMLDDBQPBECRA-DIMRZHFKSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=CN=N1 DRMLDDBQPBECRA-DIMRZHFKSA-N 0.000 claims 2
- QFLMYOYPGVRLER-UISQCYCNSA-N COC1=NC=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=C1 Chemical compound COC1=NC=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=C1 QFLMYOYPGVRLER-UISQCYCNSA-N 0.000 claims 2
- QFLMYOYPGVRLER-GUNXFRPYSA-N COC1=NC=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=C1 Chemical compound COC1=NC=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(Cl)=CC(F)=C4)C3=N2)=C1 QFLMYOYPGVRLER-GUNXFRPYSA-N 0.000 claims 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Chemical group 0.000 claims 2
- 239000000460 chlorine Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- OUMFVKNEDMFGII-GHEUYMLLSA-N (8R)-8-(3-chloro-5-fluorophenyl)-N-[(1R,5S)-3-(2-methoxypyridin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-amine Chemical compound ClC=1C=C(C=C(C=1)F)[C@H]1OCCN2C1=NC(=N2)NC1[C@H]2CN(C[C@@H]1CC2)C1=CC(=NC=C1)OC OUMFVKNEDMFGII-GHEUYMLLSA-N 0.000 claims 1
- SSQYSSOQTRMADE-REAHPQQBSA-N (8R)-8-(3-chloro-5-fluorophenyl)-N-[(1R,5S)-3-(6-methoxypyridazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-amine Chemical compound ClC=1C=C(C=C(C=1)F)[C@H]1OCCN2C1=NC(=N2)NC1[C@H]2CN(C[C@@H]1CC2)C1=CN=NC(=C1)OC SSQYSSOQTRMADE-REAHPQQBSA-N 0.000 claims 1
- DMNYTRIALSCYSN-VUBXYBDHSA-N (8R)-8-(3-chloro-5-fluorophenyl)-N-[(1R,5S)-3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-amine Chemical compound ClC=1C=C(C=C(C=1)F)[C@H]1OCCN2C1=NC(=N2)NC1[C@H]2CN(C[C@@H]1CC2)C1=NC=NC(=C1)C DMNYTRIALSCYSN-VUBXYBDHSA-N 0.000 claims 1
- OUMFVKNEDMFGII-DIMRZHFKSA-N (8S)-8-(3-chloro-5-fluorophenyl)-N-[(1R,5S)-3-(2-methoxypyridin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-amine Chemical compound ClC=1C=C(C=C(C=1)F)[C@@H]1OCCN2C1=NC(=N2)NC1[C@H]2CN(C[C@@H]1CC2)C1=CC(=NC=C1)OC OUMFVKNEDMFGII-DIMRZHFKSA-N 0.000 claims 1
- SSQYSSOQTRMADE-RJNPCAAESA-N (8S)-8-(3-chloro-5-fluorophenyl)-N-[(1R,5S)-3-(6-methoxypyridazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazin-2-amine Chemical compound ClC=1C=C(C=C(C=1)F)[C@@H]1OCCN2C1=NC(=N2)NC1[C@H]2CN(C[C@@H]1CC2)C1=CN=NC(=C1)OC SSQYSSOQTRMADE-RJNPCAAESA-N 0.000 claims 1
- 208000018282 ACys amyloidosis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- TZHWRCJKZZSICY-MFGZZSJASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4)=C4F)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4)=C4F)C3=N2)=NC=N1 TZHWRCJKZZSICY-MFGZZSJASA-N 0.000 claims 1
- SLOCFYCPEIIVMG-MFGZZSJASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC=C4F)=C4F)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC=C4F)=C4F)C3=N2)=NC=N1 SLOCFYCPEIIVMG-MFGZZSJASA-N 0.000 claims 1
- WXBDNKUJROQEHZ-MFGZZSJASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(F)=CC(F)=C4)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(F)=CC(F)=C4)C3=N2)=NC=N1 WXBDNKUJROQEHZ-MFGZZSJASA-N 0.000 claims 1
- TZHWRCJKZZSICY-MVGGYSAASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4)=C4F)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4)=C4F)C3=N2)=NC=N1 TZHWRCJKZZSICY-MVGGYSAASA-N 0.000 claims 1
- SLOCFYCPEIIVMG-MVGGYSAASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC=C4F)=C4F)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC=C4F)=C4F)C3=N2)=NC=N1 SLOCFYCPEIIVMG-MVGGYSAASA-N 0.000 claims 1
- WXBDNKUJROQEHZ-MVGGYSAASA-N CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(F)=CC(F)=C4)C3=N2)=NC=N1 Chemical compound CC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(F)=CC(F)=C4)C3=N2)=NC=N1 WXBDNKUJROQEHZ-MVGGYSAASA-N 0.000 claims 1
- KQQKMJRXNXRLPN-GHEUYMLLSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4)=C4F)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC(F)=C4)=C4F)C3=N2)=CN=N1 KQQKMJRXNXRLPN-GHEUYMLLSA-N 0.000 claims 1
- WLZZOJITXAXCRJ-GHEUYMLLSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC=C4F)=C4F)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C(C=CC=C4F)=C4F)C3=N2)=CN=N1 WLZZOJITXAXCRJ-GHEUYMLLSA-N 0.000 claims 1
- WGNAEOBGKQHHBW-GHEUYMLLSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(F)=CC(F)=C4)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@@H]3C4=CC(F)=CC(F)=C4)C3=N2)=CN=N1 WGNAEOBGKQHHBW-GHEUYMLLSA-N 0.000 claims 1
- KQQKMJRXNXRLPN-DIMRZHFKSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4)=C4F)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC(F)=C4)=C4F)C3=N2)=CN=N1 KQQKMJRXNXRLPN-DIMRZHFKSA-N 0.000 claims 1
- WLZZOJITXAXCRJ-DIMRZHFKSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC=C4F)=C4F)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C(C=CC=C4F)=C4F)C3=N2)=CN=N1 WLZZOJITXAXCRJ-DIMRZHFKSA-N 0.000 claims 1
- WGNAEOBGKQHHBW-DIMRZHFKSA-N COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(F)=CC(F)=C4)C3=N2)=CN=N1 Chemical compound COC1=CC(N(C[C@H]2CC3)C[C@H]3C2NC2=NN(CCCO[C@H]3C4=CC(F)=CC(F)=C4)C3=N2)=CN=N1 WGNAEOBGKQHHBW-DIMRZHFKSA-N 0.000 claims 1
- DMNYTRIALSCYSN-VCTRGTQWSA-N ClC=1C=C(C=C(C1)F)[C@@H]1OCCN2C1=NC(=N2)NC2[C@H]1CN(C[C@@H]2CC1)C1=NC=NC(=C1)C Chemical compound ClC=1C=C(C=C(C1)F)[C@@H]1OCCN2C1=NC(=N2)NC2[C@H]1CN(C[C@@H]2CC1)C1=NC=NC(=C1)C DMNYTRIALSCYSN-VCTRGTQWSA-N 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims 1
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- 208000017004 dementia pugilistica Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Spoj, naznačen time, da je predstavljen formulom (I)
[image]
pri čemu
R1 je halogen, C1-7 alkil, C1-7 alkil supstituiran halogenom, C1-7 alkoksi, ili C1-7 alkoksi supstituiran halogenom,
i R1 može biti različit ako je n = 2 ili 3;
m je 1 ili 2;
n je 1, 2 ili 3;
Ar je šesteročlana heteroarilna skupina, koja se bira između
[image]
,
[image]
,
[image]
pri čemu
R2 je vodik, halogen, C1−7 alkil, C1−7 alkil supstituiran halogenom, ili C1−7 alkoksi;
R3 je vodik ili halogen;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj koji ima formulu (I) prema patentnom zahtjevu 1, naznačen time, da je spoj koji ima formulu (I) spoj predstavljen formulom (Ia):
[image]
pri čemu su R1, m, n i Ar definirani kao u patentnom zahtjevu 1.
3. Spoj koji ima formulu (I) prema patentnom zahtjevu 1, naznačen time, da je spoj koji ima formulu (I) spoj predstavljen formulom (Ib):
[image]
pri čemu su R1, m, n i Ar definirani kao u patentnom zahtjevu 1.
4. Spoj koji ima formulu (I) prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da R1 je halogen.
5. Spoj koji ima formulu (I) prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da R1 je fluor ili klor.
6. Spoj koji ima formulu (I) prema bilo kojem od patentnih zahtjeva od 1 do 5, naznačen time, da n je 2 ili 3.
7. Spoj koji ima formulu (I) prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da Ar je šesteročlana heteroarilna skupina, koja se bira između
[image]
,
[image]
,
[image]
pri čemu
R2 je C1-7 alkil ili C1-7 alkoksi;
R3 je vodik.
8. Spoj koji ima formulu (I) prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da Ar je šesteročlana heteroarilna skupina, koja se bira između
[image]
,
[image]
,
[image]
pri čemu
R2 je metil ili metoksi;
R3 je vodik.
9. Spoj koji ima formulu (I) prema bilo kojem od patentnih zahtjeva od 1 do 3, naznačen time, da:
R1 je halogen;
m je 1 ili 2;
n je 2 ili 3;
Ar je šesteročlana heteroarilna skupina, koja se bira između
[image]
,
[image]
,
[image]
pri čemu
R2 je C1-7 alkil ili C1-7 alkoksi;
R3 je vodik.
10. Spoj koji ima formulu (I) prema bilo kojem od patentnih zahtjeva od 1 do 3, naznačen time, da:
R1 je fluor ili klor,
m je 1 ili 2;
n je 2 ili 3;
Ar je šesteročlana heteroarilna skupina, koja se bira između
[image]
,
[image]
,
[image]
pri čemu
R2 je metil ili metoksi;
R3 je vodik.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da je odabran iz skupine koju čine
(9R)-9-(2,3-difluorofenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(2,3-difluorofenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-9-(2,4-difluorofenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(2,4-difluorofenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-9-(2,3-difluorofenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(2,3-difluorofenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-9-(3,5-difluorofenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(3,5-difluorofenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-9-(2,4-difluorofenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(2,4-difluorofenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-9-(3,5-difluorofenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(3,5-difluorofenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metilpiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metilpiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-N-[(1R,5S)-3-(6-metilpiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-N-[(1R,5S)-3-(6-metilpiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8 -il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8 -il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(8R)-8-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8 -il]-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8S)-8-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8 -il]-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8R)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-8-(2,3,4-trifluorofenil)-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8S)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-8-(2,3,4-trifluorofenil)-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8R)-8-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8 -il]-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8S)-8-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8 -il]-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8R)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-8-(2,3,4-trifluorofenil)-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8S)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-8-(2,3,4-trifluorofenil)-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8R)-8-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8 -il]-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8S)-8-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8 -il]-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8R)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-8-(2,3,4-trifluorofenil)-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8S)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-8-(2,3,4-trifluorofenil)-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(9R)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
ili njihova farmaceutski prihvatljiva sol.
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da je odabran iz skupine koju čine
(9R)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metilpiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metilpiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-N-[(1R,5S)-3-(6-metilpiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-N-[(1R,5S)-3-(6-metilpiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8 -il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metoksipiridazin-4-il)-3-azabiciklo[3.2.1]oktan-8 -il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(8R)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-8-(2,3,4-trifluorofenil)-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8S)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-8-(2,3,4-trifluorofenil)-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8R)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-8-(2,3,4-trifluorofenil)-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(8S)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-8-(2,3,4-trifluorofenil)-6,8-dihidro-5H-[1,2,4]triazolo[5,1-c][1,4]oksazin-2-amin;
(9R)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-9-(3-kloro-5-fluoro-fenil)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-N-[(1R,5S)-3-(2-metoksi-4-piridil)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9R)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
(9S)-N-[(1R,5S)-3-(6-metilpirimidin-4-il)-3-azabiciklo[3.2.1]oktan-8-il]-9-(2,3,4-trifluorofenil)-5,6,7,9-tetrahidro-[1,2,4]triazolo[5,1-c][1,4]oksazepin-2-amin;
ili njihova farmaceutski prihvatljiva sol.
13. Postupak za pripravu spoja prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time, da obuhvaća reakciju između spoja 5
[image]
i amina 6
[image]
pri čemu su Ar, R1, n i m definirani kao u bilo kojem od patentnih zahtjeva 1 do 12, kako bi se dobio navedeni spoj koji ima formulu (I), i po želji, pretvaranje dobivenih spojeva u njihovu farmaceutski prihvatljivu sol.
14. Spoj prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time, da se primjenjuje kao terapeutski aktivna tvar.
15. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 12 i terapeutski inertni nosač.
16. Spoj prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time, da se primjenjuje u terapijskom i/ili profilaktičkom liječenju Alzheimerove bolesti, cerebralne amiloidne angiopatije, nasljednog moždanog krvarenja s amiloidozom Dutch tipa, multiinfarktne demencije, poremećaja dementia pugilistica ili Downovog sindroma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18192219 | 2018-09-03 | ||
| EP19759411.2A EP3846903B1 (en) | 2018-09-03 | 2019-09-02 | Bicyclic heteroaryl derivatives |
| PCT/EP2019/073303 WO2020048904A1 (en) | 2018-09-03 | 2019-09-02 | Bicyclic heteroaryl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231663T1 true HRP20231663T1 (hr) | 2024-03-15 |
Family
ID=63490310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231663TT HRP20231663T1 (hr) | 2018-09-03 | 2019-09-02 | Biciklički derivati heteroarila |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US12084461B2 (hr) |
| EP (1) | EP3846903B1 (hr) |
| JP (1) | JP7398435B2 (hr) |
| CN (1) | CN112566696B (hr) |
| AR (1) | AR116051A1 (hr) |
| AU (1) | AU2019336492B2 (hr) |
| BR (1) | BR112021002170A2 (hr) |
| CA (1) | CA3107593A1 (hr) |
| CL (1) | CL2021000486A1 (hr) |
| CO (1) | CO2021002415A2 (hr) |
| CR (1) | CR20210104A (hr) |
| DK (1) | DK3846903T3 (hr) |
| ES (1) | ES2966947T3 (hr) |
| FI (1) | FI3846903T3 (hr) |
| HR (1) | HRP20231663T1 (hr) |
| HU (1) | HUE064554T2 (hr) |
| IL (1) | IL281175B2 (hr) |
| LT (1) | LT3846903T (hr) |
| MA (1) | MA53541B1 (hr) |
| MX (1) | MX2021002087A (hr) |
| PE (1) | PE20210860A1 (hr) |
| PH (1) | PH12021550320A1 (hr) |
| PL (1) | PL3846903T3 (hr) |
| PT (1) | PT3846903T (hr) |
| RS (1) | RS64950B1 (hr) |
| SG (1) | SG11202102137SA (hr) |
| SI (1) | SI3846903T1 (hr) |
| TW (1) | TWI841592B (hr) |
| UA (1) | UA128482C2 (hr) |
| WO (1) | WO2020048904A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210110309A (ko) | 2018-12-27 | 2021-09-07 | 에프. 호프만-라 로슈 아게 | 엑소-tert-부틸 N-(3-아자비사이클로[3.2.1]옥탄-8-일)카르바메이트의 제조 방법 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994349A (en) | 1997-10-27 | 1999-11-30 | Howard University | 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives |
| CZ302147B6 (cs) | 1998-04-01 | 2010-11-18 | Nortran Pharmaceuticals Inc. | Aminocyklohexyletherová sloucenina, použití této slouceniny pri výrobe léciva, farmaceutická kompozice tuto slouceninu obsahující a tato sloucenina a kompozice pro použití pri lécení |
| AU2528900A (en) | 1999-02-12 | 2000-08-29 | Nortran Pharmaceuticals Inc. | Cycloalkyl amine compounds and uses thereof |
| US7507545B2 (en) | 1999-03-31 | 2009-03-24 | Cardiome Pharma Corp. | Ion channel modulating activity method |
| WO2000071528A1 (en) | 1999-05-25 | 2000-11-30 | Neurogen Corporation | 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands |
| EP1218003A4 (en) | 1999-09-13 | 2004-02-11 | David M Swope | COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY |
| US7057053B2 (en) | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
| WO2007032009A2 (en) | 2005-09-15 | 2007-03-22 | Biomas Ltd. | Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis |
| CA2686754C (en) | 2007-05-11 | 2014-10-28 | F. Hoffmann-La Roche Ag | Hetarylanilines as modulators for amyloid beta |
| EA017119B1 (ru) | 2007-10-19 | 2012-09-28 | Янссен Фармацевтика, Н.В. | МОДУЛЯТОРЫ АКТИВНОСТИ γ-СЕКРЕТАЗЫ ИЗ ГРУППЫ ПИПЕРИДИНИЛА И ПИПЕРАЗИНИЛА |
| AU2009314049B2 (en) | 2008-11-13 | 2015-03-05 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| TW201035101A (en) | 2009-02-26 | 2010-10-01 | Eisai R&D Man Co Ltd | Nitrogen-containing fused heterocyclic compound |
| WO2010138901A1 (en) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
| WO2011007756A1 (ja) * | 2009-07-13 | 2011-01-20 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| CN102484127B (zh) | 2009-09-04 | 2015-07-15 | 惠普开发有限公司 | 基于混合金属价键化合物的记忆电阻 |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| CN103874702B (zh) * | 2011-07-15 | 2015-12-09 | 杨森制药公司 | 作为γ分泌酶调节剂的经取代的吲哚衍生物 |
| US9637491B2 (en) | 2012-10-19 | 2017-05-02 | Origenis Gmbh | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors |
| CN107922437B (zh) | 2015-09-09 | 2021-12-10 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| JP6872550B2 (ja) | 2015-12-10 | 2021-05-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋されたピペリジン誘導体 |
| JP7012715B2 (ja) | 2016-06-27 | 2022-01-28 | エフ．ホフマン－ラ ロシュ アーゲー | γ－セクレターゼモジュレーターとしてのトリアゾロピリジン |
| AR109829A1 (es) | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| JP7111704B2 (ja) | 2016-11-01 | 2022-08-02 | エフ．ホフマン－ラ ロシュ アーゲー | 二環式ヘテロアリール誘導体 |
| EP3538516B1 (en) | 2016-11-08 | 2021-06-16 | F. Hoffmann-La Roche AG | Phenoxytriazoles |
| CA3047096A1 (en) | 2016-12-16 | 2018-06-21 | Pipeline Therapeutics, Inc. | Methods of treating cochlear synaptopathy |
| EP3743428B1 (en) | 2018-01-22 | 2022-01-19 | F. Hoffmann-La Roche AG | Triazolo-azepine derivatives |
-
2019
- 2019-09-02 ES ES19759411T patent/ES2966947T3/es active Active
- 2019-09-02 BR BR112021002170-1A patent/BR112021002170A2/pt unknown
- 2019-09-02 IL IL281175A patent/IL281175B2/en unknown
- 2019-09-02 HU HUE19759411A patent/HUE064554T2/hu unknown
- 2019-09-02 MA MA53541A patent/MA53541B1/fr unknown
- 2019-09-02 AR ARP190102494A patent/AR116051A1/es unknown
- 2019-09-02 LT LTEPPCT/EP2019/073303T patent/LT3846903T/lt unknown
- 2019-09-02 PT PT197594112T patent/PT3846903T/pt unknown
- 2019-09-02 UA UAA202101190A patent/UA128482C2/uk unknown
- 2019-09-02 US US17/273,278 patent/US12084461B2/en active Active
- 2019-09-02 FI FIEP19759411.2T patent/FI3846903T3/fi active
- 2019-09-02 HR HRP20231663TT patent/HRP20231663T1/hr unknown
- 2019-09-02 EP EP19759411.2A patent/EP3846903B1/en active Active
- 2019-09-02 PE PE2021000165A patent/PE20210860A1/es unknown
- 2019-09-02 SG SG11202102137SA patent/SG11202102137SA/en unknown
- 2019-09-02 CA CA3107593A patent/CA3107593A1/en active Pending
- 2019-09-02 JP JP2021512272A patent/JP7398435B2/ja active Active
- 2019-09-02 RS RS20231189A patent/RS64950B1/sr unknown
- 2019-09-02 WO PCT/EP2019/073303 patent/WO2020048904A1/en active Application Filing
- 2019-09-02 CN CN201980054254.2A patent/CN112566696B/zh active Active
- 2019-09-02 TW TW108131458A patent/TWI841592B/zh active
- 2019-09-02 CR CR20210104A patent/CR20210104A/es unknown
- 2019-09-02 MX MX2021002087A patent/MX2021002087A/es unknown
- 2019-09-02 PL PL19759411.2T patent/PL3846903T3/pl unknown
- 2019-09-02 AU AU2019336492A patent/AU2019336492B2/en active Active
- 2019-09-02 SI SI201930682T patent/SI3846903T1/sl unknown
- 2019-09-02 DK DK19759411.2T patent/DK3846903T3/da active
-
2021
- 2021-02-15 PH PH12021550320A patent/PH12021550320A1/en unknown
- 2021-02-24 CO CONC2021/0002415A patent/CO2021002415A2/es unknown
- 2021-02-26 CL CL2021000486A patent/CL2021000486A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200624T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka | |
| HRP20210770T1 (hr) | PIROLO[2,3-d]PIRIMIDINIL-, PIROLO[2,3-b]PIRAZINIL- I PIROLO[2,3-d]PIRIDINILAKRILAMIDI | |
| HRP20171140T1 (hr) | Makrociklički spojevi kao inhibitori trk kinaze | |
| EA201691343A1 (ru) | Гетероарилзамещенные никотинамидные соединения | |
| DK1966200T3 (en) | Heterocyclic JANUS kinase 3 inhibitors | |
| JP2017503867A5 (hr) | ||
| CA2954189A1 (en) | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof | |
| WO2016015604A1 (en) | Compounds as cdk small-molecule inhibitors and uses thereof | |
| JP2013512953A5 (hr) | ||
| HRP20170349T1 (hr) | Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| JP2014513139A5 (hr) | ||
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| ME02922B (me) | Novi derivati indolizina, postupak njihove proizvodnje i farmaceutske kompozicije koje ih sadrže | |
| JPWO2020201991A5 (hr) | ||
| HRP20160098T1 (hr) | Tricikliäśki spojevi | |
| JP2013531684A5 (hr) | ||
| JP2009502953A5 (hr) | ||
| HRP20201754T1 (hr) | Supstituirani pirido[3,4-b]indoli za liječenje poremećaja hrskavice | |
| HRP20240354T1 (hr) | Biciklički ketonski spojevi i postupci njihove primjene | |
| HRP20212020T1 (hr) | Derivati parazola zgušenog prstena i njihova priprema i njihova primjena u liječenju raka, upale i imunoloških bolesti | |
| JP2023524036A (ja) | ペプチジルアルギニンデイミナーゼの大環状阻害剤 | |
| HRP20231663T1 (hr) | Biciklički derivati heteroarila | |
| HRP20210095T1 (hr) | Novi derivati amino-imidazopiridina kao inhibitori janus kinaze i njihova farmaceutska upotreba | |
| JP2014528436A5 (hr) | ||
| PH12020500583B1 (en) | 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases |